Triple-negative breast cancers (TNBCs) constitute up to 20% of all breast cancers and are characterized by a lack of oestrogen receptor (ER) and progesterone receptor (PR), as well as human epidermal growth factor receptor 2 (HER2) amplification 1. This evidence concerns the gene PGR and breast carcinoma.